Evaluation of the thrombin generation potential of a recombinant factor IX Fc fusion protein (rFIXFc) in a phase 3 multi-national clinical trial

被引：0
|
作者：
Yang Buyue [1 ]
Jiang, Haiyan [1 ]
Luk, Alvin [1 ]
Pierce, Glenn F. [1 ]
Sommer, Jurg M. [1 ]
机构：
[1] Biogen Idec Inc, Cambridge Ctr 14, Cambridge, MA 02142 USA
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [41] Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype
    Driessler, Frank
    Miguelino, Maricel G.
    Pierce, Glenn F.
    Peters, Robert T.
    Sommer, Jurg M.
    BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (07) : 540 - 550
  • [42] Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B
    Powell, Jerry S.
    Perry, David
    Baker, Ross I.
    Shapiro, Amy
    Manco-Johnson, Marilyn J.
    Potts, James
    Robinson, Brian
    Mei, Baisong
    Pierce, Glenn F.
    HAEMOPHILIA, 2014, 20 : 94 - 94
  • [43] Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
    Powell, J.
    Apte, S.
    Chambost, H.
    Hermans, C.
    Jackson, S.
    Josephson, N.
    Mahlangu, J.
    Ozelo, C. M.
    Peerlinck, K.
    Allen, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 358 - 358
  • [44] Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein ( rFIXFc) in the B-LONG and Kids B-LONG Studies
    Kulkarni, Roshni
    Shapiro, Amy D.
    Windyga, Jerzy
    Ragni, Margaret V.
    Pasi, K. John
    Ozelo, Margareth Castro
    Tsao, Elisa
    Mei, Baisong
    BLOOD, 2015, 126 (23)
  • [45] Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX FC Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies
    Windyga, J.
    Kulkarni, R.
    Shapiro, A. D.
    Ragni, M. V.
    Pasi, K. J.
    Ozelo, M. C.
    Tsao, E.
    Allen, G.
    Mei, B.
    HAEMOPHILIA, 2016, 22 : 19 - 20
  • [46] Long-term safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in children with hemophilia B: Longitudinal analysis of kids B-LONG and B-YOND
    Bennett, Carolyn M.
    Nolan, Beatrice
    Kulkarni, Roshni
    Fischer, Kathelijn
    Perry, David J.
    Barnes, Christopher
    Feng, Jingyuan
    Ferrante, Francesca
    Ramirez-Santiago, Alejandra
    Mei, Baisong
    Barnowski, Chris
    Allen, Geoffrey
    HAEMOPHILIA, 2016, 22 : 47 - 47
  • [47] Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
    Santagostino, Elena
    Martinowitz, Uri
    Lissitchkov, Toshko
    Pan-Petesch, Brigitte
    Hanabusa, Hideji
    Oldenburg, Johannes
    Boggio, Lisa
    Negrier, Claude
    Pabinger, Ingrid
    Prondzinski, Mario von Depka
    Altisent, Carmen
    Castaman, Giancarlo
    Yamamoto, Koji
    Alvarez-Roman, Maria-Teresa
    Voigt, Christine
    Blackman, Nicole
    Jacobs, Iris
    BLOOD, 2016, 127 (14) : 1761 - 1769
  • [48] Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children Results of a phase 3 trial
    Kenet, Gili
    Chambost, Herve
    Male, Christoph
    Lambert, Thierry
    Halimeh, Susan
    Chernova, Tatiana
    Mancuso, Maria Elisa
    Curtin, Julie
    Voigt, Christine
    Li, Yanyan
    Jacobs, Iris
    Santagostino, Elena
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (04) : 659 - 668
  • [49] Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study
    Fischer, Kathelijn
    Kulkarni, Roshni
    Nolan, Beatrice
    Mahlangu, Johnny
    Rangarajan, Savita
    Gambino, Giulia
    Diao, Lei
    Ramirez-Santiago, Alejandra
    Pierce, Glenn F.
    Allen, Geoffrey
    LANCET HAEMATOLOGY, 2017, 4 (02): : E75 - E82
  • [50] Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
    Shapiro, Amy
    Chaudhury, Ateefa
    Wang, Michael
    Escobar, Miguel
    Tsao, Elisa
    Barnowski, Christopher
    Feng, Jing
    Jain, Nisha
    Quon, Doris V.
    HAEMOPHILIA, 2020, 26 (06) : 975 - 983
12345